ThetaPal ThetaPal

Manufacturing / Pharmaceutical Preparations

Dyne Therapeutics, Inc.

DYN

$14.25

-$1.04 (-6.80%)

Price as of Oct 16, 2026 22:30 UTC

4.9 B

Market Cap (Mid Cap)

16%

IV Rank

70.3%

Implied Volatility

Oct 29

Next Earnings

Technical Signals as of Oct 14
Bearish
0 of 7

Trend

  • Above 20-day average $16.73
  • Above 50-day average $19.15
  • Above 200-day average $19.70 · -23.7%
  • Moving averages stacked Not aligned

Momentum

  • Golden cross (50/200) Down · 5d ago
  • Momentum cross (20/50) Down · 23d ago

Volume

  • Below-average volume 0.7x avg

Price & Trend

Daily candles with EMA 20, SMA 50. Drag to zoom.

Options Activity & Greeks

Implied volatility, flow, and dealer positioning from the options market.

Put/Call Ratio

0.01

Bullish skew

Implied Volatility

70.3%

0% percentile

IV vs Realized

Options rich

30d HV 65.4%

Options Heat Map

Delta-risk grid for DYN options across strikes and expirations. Hover any cell for full Greeks.

Loading option chain data...

Insider Trades

9 buys 122 sells
Date Insider Title Type Shares Value Since Trade
Oct 02, 2026 Posner Brian S Buy 2,500 $40,000 -4.4%
Sep 08, 2026 Friedl-Naderer Johanna Sell 185 $3,493 -19.0%
Sep 08, 2026 Kerr Douglas Sell 1,290 $24,355 -19.0%
Sep 08, 2026 Cox John Sell 5,658 $106,823 -19.0%
Sep 04, 2026 Kerr Douglas Sell 3,745 $91,191 -37.2%
Sep 04, 2026 Friedl-Naderer Johanna Sell 900 $21,915 -37.2%
Aug 14, 2026 Rhodes Jason P Sell 1,359,674 $33,991,850 -38.8%
Aug 14, 2026 Rhodes Jason P Sell 478,377 $11,959,425 -38.8%
Aug 14, 2026 Rhodes Jason P Sell 322,465 $8,061,625 -38.8%
Aug 13, 2026 Rhodes Jason P Sell 268,354 $7,030,875 -41.6%

Earnings History

Date Quarter EPS Est. EPS Actual Surprise Result
Jul 30, 2026 Q2 2026 -$0.76
Jul 27, 2026 Q2 2026 -$0.76
Mar 31, 2026 Q1 2026 -$0.78 -$0.73 +6.5% Beat
Dec 31, 2025 Q4 2025 -$0.78 -$0.76 +2.3% Beat
Sep 30, 2025 Q3 2025 -$0.85 -$0.76 +10.1% Beat
Jun 30, 2025 Q2 2025 -$0.96 -$0.97 -0.6% Miss

Track DYN with ThetaPal

Get insider trade alerts, AI portfolio analysis, and options roll recommendations for DYN and your entire portfolio.